Xu Meijuan, Hao Haiping, Jiang Lifeng, Long Fang, Wei Yidan, Ji Hui, Sun Bingting, Peng Ying, Wang Guangji, Ju Wenzheng, Li Ping
State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing 210009, China; Department of Clinical Pharmacology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, No. 155 Hanzhong Road, Nanjing 210029, China.
State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 24 Tongjia Lane, Nanjing 210009, China.
Phytomedicine. 2015 Apr 15;22(4):444-51. doi: 10.1016/j.phymed.2015.02.001. Epub 2015 Feb 26.
Soluble epoxide hydrolase (sEH) has been demonstrated to be a key enzyme involved in the pathologic development of several cardiovascular diseases and inflammation, and inhibition of sEH is therefore very helpful or crucial for the treatment of ischemia-reperfusion injury, cardiac hypertrophy, hypertension and inflammation. Danshen, the dried root of Salvia miltiorrhiza (Fam. Labiatae), has been used for the treatment of cardiovascular and cerebrovascular diseases in China and other countries for hundreds of years. Recent studies indicated that Danshen and its preparations also have potential for the management of inflammation. However, little information is available about the possibility of Danshen and its components on sEH inhibition.
Danshen extracts and its constituents were tested for sEH inhibition using its physiological substrate, 8,9-EET, based on a LC-MS/MS assay in this study.
Among the tested 15 compounds, tanshinone IIA and cryptotanshinone were found to be the potent (Ki = 0.87 μM) and medium (Ki = 6.7 μM) mixed-type inhibitors of sEH, respectively. Salvianolic acid C (Ki = 8.6 μM) was proved to be a moderate noncompetitive sEH inhibitor. In consistent with the inhibition results of the pure compounds, the 75% ethanol extract of Danshen (EE, IC50 = 86.5 μg/ml) which contained more tanshinone IIA and cryptotanshinone exhibited more potent inhibition on sEH than the water extract (WE, IC50 > 200 μg/ml) or 1 M NaHCO3 (BE, IC50 > 200 μg/ml) extract.
These data indicated that using the ethanol fraction of Danshen and increasing the amounts of tanshinone IIA, cryptotanshinone and salvianolic acid C, especially the contents of tanshinone IIA in Danshen extract or preparations to enhance the inhibitory effects on sEH might be efficient ways to improve its cardiovascular protective and anti-inflammatory effects, and that herbal medicines could be an untapped reservoir for sEH-inhibition agents and developing sEH inhibitors from the cardiovascular protective and anti-inflammatory herbs is a promising approach.
可溶性环氧化物水解酶(sEH)已被证明是参与多种心血管疾病和炎症病理发展的关键酶,因此抑制sEH对治疗缺血再灌注损伤、心肌肥厚、高血压和炎症非常有帮助或至关重要。丹参,即唇形科植物丹参的干燥根,在国内外已被用于治疗心脑血管疾病数百年。最近的研究表明,丹参及其制剂在炎症管理方面也具有潜力。然而,关于丹参及其成分抑制sEH的可能性,目前可用信息较少。
本研究基于液相色谱-串联质谱法,使用sEH的生理底物8,9-环氧二十碳三烯酸(8,9-EET)检测丹参提取物及其成分对sEH的抑制作用。
在所测试的15种化合物中,丹参酮IIA和隐丹参酮分别被发现是sEH的强效(Ki = 0.87 μM)和中度(Ki = 6.7 μM)混合型抑制剂。丹酚酸C(Ki = 8.6 μM)被证明是一种中度非竞争性sEH抑制剂。与纯化合物的抑制结果一致,含有较多丹参酮IIA和隐丹参酮的丹参75%乙醇提取物(EE,IC50 = 86.5 μg/ml)对sEH的抑制作用比水提取物(WE,IC50 > 200 μg/ml)或1 M碳酸氢钠提取物(BE,IC50 > 200 μg/ml)更强。
这些数据表明,使用丹参的乙醇提取物并增加丹参酮IIA、隐丹参酮和丹酚酸C的含量,特别是丹参提取物或制剂中丹参酮IIA的含量,以增强对sEH的抑制作用,可能是提高其心血管保护和抗炎作用的有效方法,并且草药可能是sEH抑制剂的未开发来源,从具有心血管保护和抗炎作用的草药中开发sEH抑制剂是一种有前景的方法。